Total Reports
97
Above-median volume
Breed profile · FDA CVM July 2026 extract
Adverse-event filings for Atlantic Salmon (Salmo salar) (Fish) in the FDA Center for Veterinary Medicine openFDA extract. Browse fish breeds, reactions, and outcomes below.
By recorded gender -- every report on file for Atlantic Salmon (Salmo salar), no filtering.
Data updated September 2026
The verdict
According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Atlantic Salmon (Salmo salar) is #1 of 275 breeds with at least 50 reports by highest death-coded share (99.0%) at report rank #233 of 510; separately, Retriever - Labrador is #1 by total reports at 93,675 (death-coded-share rank 195).
Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.
Release-over-release change
PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Atlantic Salmon (Salmo salar) has 97 reports now versus 97 in that prior snapshot: 0 the same number of (0.0%).
This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.
Subscribe to Atlantic Salmon (Salmo salar) changesTotal Reports
97
Above-median volume
Deaths Reported
96
of 97 reports
Death-coded share of reports
99.0%
Highest death-coded share
Avg Age at Report
0.7 yr
0.4 kg avg weight
99.0% of 97 atlantic salmon (salmo salar) reports involved a death outcome.
Read alongside breed popularity, veterinary access, and owner awareness, these shape how many events ever reach the FDA. The comparison line marks the cross-breed median death-coded share (4.8%) among breeds with 50 or more reports; values above it suggest higher reporting bias toward severe outcomes, not necessarily higher true mortality.
| Year | Reports | Trend |
|---|---|---|
| 2015 | 2 | |
| 2016 | 16 | |
| 2017 | 12 | |
| 2018 | 7 | |
| 2019 | 10 | |
| 2020 | 16 | |
| 2021 | 14 | |
| 2022 | 9 | |
| 2023 | 10 | |
| 2024 | 1 | |
Signature read: Atlantic Salmon (Salmo salar)'s 99.0% death-coded share is in the upper third of the ≥50-report cohort (median 4.8%). According to FDA CVM filings indexed on PlainBreed as of July 2026 extract, Atlantic Salmon (Salmo salar) sits at #233 of 510 by report volume among all breeds and #1 of 5 among fish breeds, with 97 reports and 96 (99.0%) death-coded. On death-coded share among breeds with ≥50 reports, it ranks #1 of 275. Mean age at report: 0.7 years, average weight 0.4 kg (0.9 lbs).
Top reported signs: Death (69), IGA Animal mortality greater than expected (41), Fish body deformity (31). Most-referenced drug: Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) (88 reports), followed by Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage (7) and Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A Locus In The Eo-1A Lineage) (1).
Outcome coding on 115 status-recorded reports is dominated by Died (60.0%). Annual submissions ranged 1-2,024 across 10 years on file.
Two openFDA-derived peer sets for Atlantic Salmon (Salmo salar), both outside the Fish family so the neighborhoods are not species containment (the similar-volume list above stays within species).
Nearest other-species breeds with ≥50 reports (99.0% death-coded here).
Nearest other-species breeds by reported average weight (0.4 kg here).
What to do with this fish
A report does not prove a drug caused the reaction, and popular breeds simply generate more reports.
Compare a breed's report volume against how common the breed is before drawing conclusions. See our methodology for how the death-coded share and rankings are computed, or read breed-specific reporting patterns and FDA CVM reporting.
Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025
Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →